Silverfin false false 30/09/2024 01/10/2023 30/09/2024 Malcolm Francis Barratt-Johnson 02/09/2010 05 March 2025 no description of principal activity 07364364 2024-09-30 07364364 bus:Director1 2024-09-30 07364364 2023-09-30 07364364 core:CurrentFinancialInstruments 2024-09-30 07364364 core:CurrentFinancialInstruments 2023-09-30 07364364 core:Non-currentFinancialInstruments 2024-09-30 07364364 core:Non-currentFinancialInstruments 2023-09-30 07364364 core:ShareCapital 2024-09-30 07364364 core:ShareCapital 2023-09-30 07364364 core:RetainedEarningsAccumulatedLosses 2024-09-30 07364364 core:RetainedEarningsAccumulatedLosses 2023-09-30 07364364 core:PatentsTrademarksLicencesConcessionsSimilar 2023-09-30 07364364 core:PatentsTrademarksLicencesConcessionsSimilar 2024-09-30 07364364 core:Vehicles 2023-09-30 07364364 core:ComputerEquipment 2023-09-30 07364364 core:Vehicles 2024-09-30 07364364 core:ComputerEquipment 2024-09-30 07364364 2023-10-01 2024-09-30 07364364 bus:FilletedAccounts 2023-10-01 2024-09-30 07364364 bus:SmallEntities 2023-10-01 2024-09-30 07364364 bus:AuditExemptWithAccountantsReport 2023-10-01 2024-09-30 07364364 bus:PrivateLimitedCompanyLtd 2023-10-01 2024-09-30 07364364 bus:Director1 2023-10-01 2024-09-30 07364364 core:PatentsTrademarksLicencesConcessionsSimilar core:TopRangeValue 2023-10-01 2024-09-30 07364364 core:Vehicles 2023-10-01 2024-09-30 07364364 core:ComputerEquipment core:TopRangeValue 2023-10-01 2024-09-30 07364364 2022-10-01 2023-09-30 07364364 core:PatentsTrademarksLicencesConcessionsSimilar 2023-10-01 2024-09-30 07364364 core:ComputerEquipment 2023-10-01 2024-09-30 iso4217:GBP xbrli:pure

Company No: 07364364 (England and Wales)

PHARMAMEDIC CONSULTANCY LIMITED

Unaudited Financial Statements
For the financial year ended 30 September 2024
Pages for filing with the registrar

PHARMAMEDIC CONSULTANCY LIMITED

Unaudited Financial Statements

For the financial year ended 30 September 2024

Contents

PHARMAMEDIC CONSULTANCY LIMITED

COMPANY INFORMATION

For the financial year ended 30 September 2024
PHARMAMEDIC CONSULTANCY LIMITED

COMPANY INFORMATION (continued)

For the financial year ended 30 September 2024
DIRECTOR Malcolm Francis Barratt-Johnson
REGISTERED OFFICE The London Bioscience Innovation Centre
2 Royal College Street
London
NW1 0NH
United Kingdom
COMPANY NUMBER 07364364 (England and Wales)
ACCOUNTANT Gravita Essex Limited
Treviot House
186-192 High Road
Ilford
Essex
IG1 1LR
United Kingdom
PHARMAMEDIC CONSULTANCY LIMITED

BALANCE SHEET

As at 30 September 2024
PHARMAMEDIC CONSULTANCY LIMITED

BALANCE SHEET (continued)

As at 30 September 2024
Note 2024 2023
£ £
Fixed assets
Intangible assets 3 4,756 3,516
Tangible assets 4 8,374 8,717
13,130 12,233
Current assets
Debtors 5 337,466 280,017
Cash at bank and in hand 6 30,363 44,202
367,829 324,219
Creditors: amounts falling due within one year 7 ( 256,881) ( 238,519)
Net current assets 110,948 85,700
Total assets less current liabilities 124,078 97,933
Creditors: amounts falling due after more than one year 8 ( 122,292) ( 95,617)
Net assets 1,786 2,316
Capital and reserves
Called-up share capital 100 100
Profit and loss account 1,686 2,216
Total shareholders' funds 1,786 2,316

For the financial year ending 30 September 2024 the Company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:

The financial statements of Pharmamedic Consultancy Limited (registered number: 07364364) were approved and authorised for issue by the Director on 05 March 2025. They were signed on its behalf by:

Malcolm Francis Barratt-Johnson
Director
PHARMAMEDIC CONSULTANCY LIMITED

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 30 September 2024
PHARMAMEDIC CONSULTANCY LIMITED

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 30 September 2024
1. Accounting policies

The principal accounting policies are summarised below. They have all been applied consistently throughout the financial year and to the preceding financial year, unless otherwise stated.

General information and basis of accounting

These financial statements have been prepared in accordance with the provisions of Section 1A "Small Entities" of Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006.

Turnover

Turnover represents the total invoice value, excluding value added tax, of sales made during the year.

Taxation

Current tax
Current tax is provided at amounts expected to be paid (or recoverable) using the tax rates and laws that have been enacted or substantively enacted at the Balance Sheet date.

Deferred tax
Deferred tax arises as a result of including items of income and expenditure in taxation computations in periods different from those in which they are included in the Company's financial statements. Deferred tax is provided in full on timing differences which result in an obligation to pay more or less tax at a future date, at the average tax rates that are expected to apply when the timing differences reverse, based on current tax rates and laws. Deferred tax assets and liabilities are not discounted.

The carrying amount of deferred tax assets are reviewed at each reporting date and a valuation allowance is set up against deferred tax assets so that the net carrying amount equals the highest amount that is more likely than not to be recovered based on current or future taxable profit.

Intangible assets

Intangible assets are stated at cost or valuation, net of amortisation and any provision for impairment. Amortisation is provided on all intangible assets at rates to write off the cost or valuation of each asset over its expected useful life as follows:

Trademarks, patents and licences 10 years straight line
Tangible fixed assets

Tangible fixed assets are stated at cost or valuation, net of depreciation and any provision for impairment. Depreciation is provided on all tangible fixed assets, other than investment property and freehold land, at rates calculated to write off the cost or valuation, less estimated residual value, of each asset on a straight-line or reducing balance basis over its expected useful life, as follows:

Vehicles 25 % reducing balance
Computer equipment 4 years straight line

Residual value represents the estimated amount which would currently be obtained from disposal of an asset, after deducting estimated costs of disposal, if the asset were already of the age and in the condition expected at the end of its useful life.

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

Leases

Hire purchase and leasing commitments

Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

Pension costs and other post-retirement benefits

The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

2. Employees

2024 2023
Number Number
Monthly average number of persons employed by the Company during the year, including the director 4 4

3. Intangible assets

Trademarks, patents
and licences
Total
£ £
Cost
At 01 October 2023 5,333 5,333
Additions 1,873 1,873
At 30 September 2024 7,206 7,206
Accumulated amortisation
At 01 October 2023 1,817 1,817
Charge for the financial year 633 633
At 30 September 2024 2,450 2,450
Net book value
At 30 September 2024 4,756 4,756
At 30 September 2023 3,516 3,516

4. Tangible assets

Vehicles Computer equipment Total
£ £ £
Cost
At 01 October 2023 14,395 10,198 24,593
Additions 0 2,940 2,940
Disposals 0 ( 4,240) ( 4,240)
At 30 September 2024 14,395 8,898 23,293
Accumulated depreciation
At 01 October 2023 8,322 7,554 15,876
Charge for the financial year 1,518 1,218 2,736
Disposals 0 ( 3,694) ( 3,694)
At 30 September 2024 9,840 5,079 14,919
Net book value
At 30 September 2024 4,555 3,819 8,374
At 30 September 2023 6,073 2,644 8,717

5. Debtors

2024 2023
£ £
Trade debtors 88,178 44,869
Corporation tax 28,421 28,421
Other debtors 220,867 206,727
337,466 280,017

The debts that were subject to invoice discounting for the company at the year end amounted to £72,347 (2023: £44,710).

6. Cash and cash equivalents

2024 2023
£ £
Cash at bank and in hand 30,363 44,202
Less: Bank overdrafts ( 62,792) ( 39,531)
(32,429) 4,671

7. Creditors: amounts falling due within one year

2024 2023
£ £
Bank loans and overdrafts 73,441 50,179
Trade creditors 29,839 51,170
Taxation and social security 57,402 36,375
Other creditors 96,199 100,795
256,881 238,519

8. Creditors: amounts falling due after more than one year

2024 2023
£ £
Bank loans 6,700 16,845
Other creditors 115,592 78,772
122,292 95,617

9. DIRECTOR'S ADVANCES, CREDITS AND GUARANTEES

Director 1

2024 2023
£ £
Amounts advanced 112,468 105,252
Amounts repaid (109,811) (90,266)

Interest was charged on all loans at HMRC approved rates.

10. Secured Debts

The following secured debts are included within creditors:

2024 2023
£ £
Bank loans (17,349) (27,493)
Invoice discounting (62,792) (39,531)
(80,141) (67,024)

The invoice discounting is secured over the fixed and floating charge over all the assets of the business.